Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged material misstatements regarding its drug setrusumab, affecting investors who purchased stock between August 3, 2023, and December 26, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 (N.D. Cal.) [1] - Investors have until April 6, 2026, to file for lead plaintiff status [1] Allegations - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, downplaying the risk of failure in achieving statistically significant results in the Phase III Orbit study [1] - It is claimed that Ultragenyx's optimism regarding the study's results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [1] - The lawsuit asserts that the positive statements made by the company about its business and prospects were materially misleading and lacked a reasonable basis [1] Investor Actions - Investors can retain counsel of their choice, contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, or file to be lead plaintiff by the April 6, 2026 deadline [1] - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Mattel, Inc. for potential violations of federal securities laws, particularly concerning the company's financial reporting and disclosures [1]. Group 1: Investigation Details - The investigation is initiated on behalf of investors who may have incurred losses related to Mattel's stock [1]. - The focus of the investigation is on the fourth quarter and full year 2025 results reported by the company on February 10, 2026 [1].

Core Viewpoint - A class action lawsuit has been announced against PayPal Holdings, Inc. for securities fraud, involving investors who purchased common stock between February 25, 2025, and February 2, 2026, with the opportunity for affected investors to seek compensation without upfront costs [1]. Group 1: Lawsuit Details - The lawsuit claims that PayPal's management provided misleading information regarding the company's financial targets for 2027 and the growth potential of its Branded Checkout segment [1]. - Defendants allegedly made overly optimistic statements about PayPal's ability to capitalize on growth opportunities while concealing adverse facts about the salesforce's readiness to execute these plans [1]. - The lawsuit asserts that when the true state of PayPal's salesforce was revealed, investors suffered damages due to the misleading information provided [1]. Group 2: Legal Representation - Investors wishing to join the class action must act by April 20, 2026, to serve as lead plaintiffs, representing other class members in the litigation [1]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its achievements in securities class action settlements [1].

Company Overview - Navan, Inc. (NASDAQ: NAVN) provides AI-powered travel and expense management software and conducted its IPO in October 2025, raising $750 million by selling 30 million shares at $25.00 per share [1]. Financial Performance - In its first quarterly financial results as a public company reported on December 15, 2025, Navan disclosed a GAAP net loss of $225 million, compared to a net loss of $42 million in the third quarter of fiscal year 2025 [1]. - The company's usage yield declined to 6.9% from 7.5% the previous year [1]. Stock Market Reaction - Following the financial results announcement and the news of the departure of Chief Financial Officer Amy Butte, Navan's stock price fell nearly 12% to close at $12.90 per share, significantly below its IPO price [1].

Core Viewpoint - Hub Group, Inc. is under investigation for potential violations of federal securities laws following a significant accounting error that led to a sharp decline in its stock price [1]. Financial Performance - Hub Group reached a 52-week high of $48.96 per share on February 3, 2026, but saw its shares drop to around $37 just three days later, resulting in a loss of approximately $12 per share [2]. - The company's Q4 2025 earnings per share were reported at $0.45, slightly above the consensus estimate of $0.44, and revenue exceeded expectations. However, this positive result was overshadowed by the disclosure of a restatement affecting three prior quarters and an estimated $77 million in understated costs [4]. Analyst Reactions - Stifel downgraded Hub Group from Buy to Sell, reducing its price target from $52 to $27, a 48% decrease, citing the accounting error as a significant blow to confidence in the company's financials [3]. - Baird also downgraded its rating from Outperform to Neutral, cutting its target from $47 to $29, a 38% reduction, which contributed to increased selling pressure on the stock [3].

Core Viewpoint - The Varonis Systems, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth potential, leading to significant stock price declines following disappointing financial results [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Molchanov v. Varonis Systems, Inc., and it involves purchasers of Varonis common stock from February 4, 2025, to October 28, 2025 [1]. - Investors have until March 9, 2026, to apply for lead plaintiff status in the lawsuit [1]. - The lawsuit alleges that Varonis and its executives violated the Securities Exchange Act of 1934 [1]. Group 2: Allegations Against Varonis - The lawsuit claims that Varonis misrepresented its revenue projections and growth potential while downplaying risks associated with seasonality and macroeconomic factors [3]. - It is alleged that Varonis' optimistic reports regarding growth and sales effectiveness were not reflective of the company's actual performance [3]. - Following the release of third-quarter results on October 28, 2025, which fell short of expectations, Varonis lowered its full-year guidance, resulting in a nearly 49% drop in stock price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Varonis stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. - Robbins Geller Rudman & Dowd LLP, the firm handling the case, is a leading class action firm with a strong track record in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [6].

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CoreWeave, Inc. (NASDAQ: CRWV) securities between March 28, 2025 and December 15, 2025, inclusive (the “Class Period”), have until Friday, March 13, 2026 to seek appointment as lead plaintiff of the CoreWeave class action lawsuit. Captioned Masaitis v. CoreWeave, Inc., No. 26-cv-00355 (D.N.J.), the CoreWeave class action lawsuit charges CoreWeave as well as certain of CoreWeave’s top execu ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. regarding possible recovery of investor losses under federal securities laws following a significant stock price decline after trial results announcement [1][4]. Group 1: Investigation Details - The investigation focuses on Ocular's executive officers and their compliance with federal securities laws [1][4]. - Ocular announced topline results from its SOL-1 Phase 3 trial on February 17, 2026, revealing that 74% of patients maintained vision at nine months, 66% at twelve months, and approximately 69% were rescue-free at 52 weeks [3]. - Following the announcement, Ocular's stock price declined approximately 27% [3]. Group 2: Law Firm Background - Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with multiple offices across the United States, representing both individual and institutional investors [5]. - The firm has been ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, having recovered approximately $90.725 million for clients in cases where it served as lead or co-lead counsel [6].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Helen of Troy Limited regarding possible recoveries of investor losses under federal securities laws [1]. Group 1: Investigation Details - The investigation focuses on whether Helen of Troy's executive officers complied with federal securities laws following significant financial disclosures [1][3]. - On October 9, 2025, Helen of Troy reported $326.4 million in pre-tax asset impairment charges for the quarter ended August 31, 2025, leading to a stock price decline of approximately 25% [3]. Group 2: Investor Participation - Investors who purchased Helen of Troy securities and suffered losses are encouraged to join the investigation, with no cost or obligation [2]. Group 3: Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, with multiple offices across the United States [4]. - The firm has been ranked among the Top 10 Plaintiff Law Firms in 2024, recovering approximately $90.7 million for clients in securities cases [5].

Core Viewpoint - Picard Medical, Inc. (PMI) shareholders who incurred losses have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed fraudulent activities by the company [1] Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that between September 2, 2025, and October 31, 2025, Picard Medical failed to disclose critical information to investors, including involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals [1] - It is claimed that insiders or affiliates used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] - As a result, the positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]